MDoutlook is excited to announce a strategic collaboration with Justin Boag of infill Switzerland. Justin will represent MDoutlook in Europe, to further strengthen our significant global experience and expertise, and to provide a stronger touch point with our European clients.
Based in Basel (Switzerland), Justin brings significant experience of the European oncology and hematology market to MDoutlook. This is gained from his work at infill Switzerland and through his leadership positions at Roche, AstraZeneca and GE Healthcare.
Justin has worked with several novel therapeutics approaches in oncology and hematology including: monoclonal antibodies, targeted TKI therapies, supportive care and hormonal therapies. These have been across a wide range of disease indications and states including solid tumors (incl. breast, colorectal, gastric, lung and prostate), hematologic malignancies (incl. non-Hodgkin and Hodgkin Lymphoma), and supportive care.
Commented on the strategic collaboration, Justin says “I am really excited to be working with the MDoutlook team to strengthen their European presence even further. MDoutlook is a world class Business Insights company offering significant insight from their team of in-house medical experts and a governance panel of top ThoughtLeaders, as well as experience from over 260 bespoke projects for a wide range of Pharma clients. I am delighted to be part of their team.”
Jan Heybroek, President of MDoutlook, welcomes Justin “MDoutlook already has significant experience in Europe providing high quality research and insight to dozens of large and mid-size life science companies. Working with Justin enhances the breadth and depth of our experience and our value to our clients) to our clients, including global commercial leadership of important cancer drugs, such as Avastin. We believe strongly that this further strengthens the high quality of our insight delivered through our panel of 28,000 cancer treaters in Europe.”